Beyond PSMA:

What the graphic shows:

The flowchart maps out:

1. Entry point: PSA rising despite Pluvicto/Actinium

2. Critical first decision: Comprehensive genomic profiling (the lynchpin of precision medicine)

3. Three molecular outcomes:

   • BRCA1/2 or ATM mutation → PARP inhibitors (best data: 19–24 month OS, 43–44% PSA50 response)
   • MSI-H or dMMR → Checkpoint inhibitors like Pembrolizumab (50%+ response in this small subset)
   • No actionable HRR mutation → Splits by performance status → either emerging non-PSMA targets (FG-3246 CD46-ADC, JANX007) or chemotherapy (cabazitaxel ± carboplatin)

4. Secondary assessment: PSMA imaging status (all PSMA-positive vs. mixed/PSMA-negative)

   • PSMA-positive nodes → Consider re-dosing PSMA therapy or sequencing with PARP/chemo
   • PSMA-negative/mixed → Prefer non-PSMA mechanisms (FG-3246, cabazitaxel)

5. Clinical trial opportunities: All pathways funnel through available trials

6. Final recommendation: Three actionable next steps

Key message embedded in the graphic:

Chemotherapy is not desperation—it's a rational choice when:

• No HRR mutations are found AND
• Patient has good performance status but isn't eligible for/interested in clinical trials

But genetic testing is non-negotiable because:

• BRCA mutations → PARP inhibitors outperform chemotherapy significantly
• MSI-H status → Completely different therapeutic class (immunotherapy)
• Either finding transforms the treatment approach

Possibilities When Pluvicto and Actinium Fail 

in mCRPC with Lymph Node Metastases

BLUF (Bottom Line Up Front): 

If your metastatic castration-resistant prostate cancer has progressed despite Pluvicto and Actinium, chemotherapy is not your only option—though it remains a legitimate one. The most promising immediate alternatives depend on genetic testing results: PARP inhibitors can extend survival significantly if DNA repair genes (BRCA1/2, ATM) are mutated; emerging antibody-drug conjugates targeting CD46 show clinical activity independent of PSMA expression; and combination immunotherapy approaches are being refined in clinical trials. The critical first step is comprehensive genomic profiling to guide the best sequencing of remaining options. Chemotherapy with cabazitaxel remains highly effective but need not be viewed as a final resort—it can be part of a rational treatment sequence when other options don't fit your molecular profile.

The Real Picture: Why PSMA Therapy Fails

When you've tried both Pluvicto (lutetium-177 PSMA-617) and Actinium-225 PSMA therapy and your PSA continues to rise, the first and most important question is not "What's left?" but rather "Why did PSMA therapy fail?" The answer shapes your next move.

Up to 15–20% of prostate cancers lose PSMA expression entirely, and even within individual patients with multiple metastatic sites, PSMA expression varies dramatically from lesion to lesion. In clinical trials, this heterogeneity is a known problem: some of your tumor cells might have extremely high PSMA uptake (SUV values of 20–30 or more), while others have virtually none. The PSMA-negative lesions are invisible to both Pluvicto and Actinium, and they continue to grow while you're being treated with these PSMA-targeted therapies.

There's also a metabolic shift issue. Researchers have documented cases where tumors initially light up brilliantly on PSMA PET/CT scans (with SUVmax values exceeding 90), then progress despite PSMA treatment—but on follow-up FDG PET/CT imaging, the same lesions show lower, heterogeneous fluorodeoxyglucose uptake, indicating the cancer cells are shifting their metabolic behavior. This suggests your cancer may be evolving into a more aggressive phenotype that's less dependent on PSMA signaling.

Why does this matter? Because it means your next therapy should target a different mechanism entirely, not just try to push harder on the PSMA lever.

Option 1: Genetic Testing and PARP Inhibitors—Don't Skip This Step

If you haven't had comprehensive somatic genetic testing of your tumor (or circulating tumor DNA), this is your most time-sensitive next move. The results can genuinely change your prognosis.

Approximately 23% of men with mCRPC harbor deleterious mutations in homologous recombination repair (HRR) genes, including BRCA1, BRCA2, ATM, PALB2, and others. If your tumor carries mutations in BRCA1 or BRCA2, PARP inhibitors offer something remarkable: men with BRCA2-mutated mCRPC who receive olaparib show median overall survival improvements of 5–6 months compared to standard hormonal therapy, and many achieve PSA responses exceeding 50% decline.

PARP Inhibitor Performance in mCRPC:

• Olaparib (Lynparza): In the PROFOUND trial, men with BRCA1/2 mutations showed median rPFS of 7.4 months (vs. 3.6 months with standard therapy) and median OS of 19 months (vs. 14 months). Response rates in BRCA2-mutated disease: 43.9% achieved PSA50 (≥50% PSA decline).
• Rucaparib (Rubraca): FDA-approved for BRCA-mutated mCRPC. TRITON3 trial showed robust benefit in men who had progressed on androgen receptor pathway inhibitors.
• Talazoparib with Enzalutamide (TALAPRO-2): Now approved as first-line therapy for men with HRR alterations; can be used earlier in disease course if diagnosed with genetic mutations upfront.

Here's the critical nuance: BRCA2 mutations are found in 8–10% of mCRPC, while BRCA1 is only 1–2%. Response rates are considerably more robust in BRCA2 carriers, and this difference is clinically meaningful. Some BRCA1 cases show biallelic loss in the tumor (complete loss of both copies), which predicts excellent PARP response, while others retain one functional copy and respond less well. Genetic counseling and clear communication with your oncologist about the interpretation of your results matters.

The germline vs. somatic question: It doesn't matter much. Outcomes from the PROFOUND, TRITON2, and TOPARP-B trials show comparable benefit whether the BRCA mutation is inherited (germline) or found only in the tumor (somatic). Both warrant PARP inhibitor treatment.

If your genomic testing reveals mutations in other HRR genes beyond BRCA1/2—such as ATM, PALB2, CHEK2, or CDK12—the picture is more complex. Some of these show benefit with PARP inhibitors, though the evidence is less robust than for BRCA mutations. This is where discussion with a medical oncologist who specializes in precision oncology becomes invaluable.

Option 2: Emerging Antibody-Drug Conjugates—A Non-PSMA Path Forward

One of the most exciting developments for men whose disease has escaped PSMA targeting is the emergence of antibody-drug conjugates (ADCs) that hit entirely different tumor targets.

FG-3246 (CD46-targeting ADC): This is perhaps the most clinically relevant right now. CD46 is a cell-surface antigen expressed at high levels in advanced prostate cancer and is independent of PSMA status—meaning your PSMA-negative metastases might still be vulnerable to this drug. A Phase I study published in the Journal of Clinical Oncology in 2025 showed that FG-3246 has an acceptable safety profile and demonstrates clinical activity in heavily pre-treated mCRPC patients. FibroGen (the manufacturer) is on track to initiate a Phase 2 monotherapy study by mid-2025, with results expected in the second half of 2025. A combination trial pairing FG-3246 with enzalutamide is also underway. For patients in lymph node-only disease, this represents a potentially game-changing option because it bypasses the PSMA heterogeneity problem entirely.

JANX007 (PSMA/CD3 Bispecific T-Cell Engager): This is a newer class of agent—a bispecific antibody that binds both to PSMA on tumor cells and to CD3 on T cells, essentially recruiting your immune system to attack the cancer. The ENGAGER-PSMA-01 trial is evaluating JANX007 in approximately 105 mCRPC patients; primary completion is expected in March 2025. The appeal is that even if PSMA is present, this drug brings T-cell killing power to the party.

Novel radioconjugates: JNJ-69086420 (an antibody radioconjugate targeting human kallikrein 2, or hK2, labeled with actinium-225) represents another angle: hK2 is more strongly associated with prostate tumors than PSA itself and is highly expressed on poorly differentiated tumor cells. This is in early development but represents the kind of "next-generation target" that researchers are pursuing for post-PSMA therapy patients.

Option 3: Chemotherapy—Reframed

Let's address the emotional weight of this option directly: Is chemotherapy "desperation"? No. It's a rational next step when PSMA-targeted therapy has failed and your tumor hasn't revealed a clear genetic vulnerability to PARP inhibitors.

Cabazitaxel (Jevtana): This is the standard chemotherapy for mCRPC after docetaxel failure. In the TROPIC trial, cabazitaxel improved overall survival compared to mitoxantrone in post-docetaxel patients. For men with unfavorable prognostic factors or high disease burden, this is still considered a reasonable option by both NCCN and ASCO guidelines.

The TheraP trial comparison: A landmark Australian Phase II trial directly compared Pluvicto (177Lu-PSMA-617) to cabazitaxel in 200 men with post-docetaxel mCRPC. Both had received prior androgen receptor pathway inhibitors. Key findings:

• Pluvicto: 49% objective response rate, improved PSA progression-free survival
• Cabazitaxel: 24% objective response rate
• The trial was not powered to detect an overall survival difference, and none was observed.

What this tells you: Pluvicto performed better in this head-to-head comparison, which is why it moved to earlier lines of therapy. But cabazitaxel remains effective, and for men who are Pluvicto-refractory and in good performance status, chemotherapy can still provide meaningful PSA responses and disease control.

Combination approaches: There's emerging interest in combining cabazitaxel with carboplatin in men with high-volume visceral metastases, as this combination has shown rapid tumor shrinkage in some cases. A Phase 1/2 trial (LuCAB) is evaluating the combination of cabazitaxel with 177Lu-PSMA-617 itself, which suggests that even after failure on one PSMA regimen, combining it with chemotherapy might re-sensitize disease. This is speculative at present, but the concept is being tested.

Important caveat on chemotherapy: Cabazitaxel carries risks of bone marrow suppression, neuropathy, and infection. Your overall health, renal function, and performance status matter enormously. If you're in excellent functional condition, chemotherapy may be reasonable. If you've had significant toxicities from prior docetaxel, the risk-benefit calculus shifts.

Option 4: Clinical Trials and Immunotherapy Combinations

The landscape of clinical trials for post-PSMA therapy mCRPC is expanding rapidly. If you're fit enough and motivated to pursue investigational options, several are worth discussing with your oncologist.

Radiopharmaceutical combinations: Trials are now testing 177Lu-PSMA-617 in combination with immunotherapy (checkpoint inhibitors like ipilimumab and nivolumab) in men with mCRPC. The hypothesis is that radioligand therapy can unmask tumor antigens and prime the immune system, potentially synergizing with checkpoint inhibitors. The ANZUP2001 trial is one example; primary completion is expected in late 2024 to early 2025.

Bipolar androgen therapy (BAT) plus nivolumab: This is a more niche approach but worth knowing about. The COMBAT trial tested sequential treatment with BAT (alternating cycles of high-dose testosterone and castration) followed by the checkpoint inhibitor nivolumab in men with advanced mCRPC. The concept is that BAT may "reprogram" the immune microenvironment to become more responsive to checkpoint blockade. Results in mCRPC have been modest, but it's an example of creative combination thinking.

MSI-H and dMMR screening: If your tumor undergoes genomic testing and is found to be microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), you may be eligible for pembrolizumab (Keytruda), a PD-1 checkpoint inhibitor approved for any solid tumor with these features. This is rare in prostate cancer, but it happens, and when it does, response rates can be dramatic. All mCRPC patients should be screened for this.

CDK12 alterations: Similarly, men whose tumors carry inactivating CDK12 mutations represent a distinct molecular subset. Expert panels are divided on whether checkpoint inhibitors should be preferred over standard mCRPC therapies in this group, but it's another reason genomic profiling is essential.

The Sequencing Question: What Order Makes Sense?

The honest answer is that optimal sequencing for mCRPC regimens is not yet settled by high-quality evidence. However, current expert consensus (from NCCN, ASCO, and international urology meetings) offers rough guidance:

If You Have...	Next Step Is Often...	Rationale
BRCA1/2 or ATM mutation (somatic or germline)	PARP inhibitor monotherapy	Highest-impact molecular finding; strong evidence of survival benefit
No HRR mutations; no MSI-H; no CDK12 alteration	FG-3246 (CD46-ADC) if available/eligible, OR cabazitaxel	FG-3246 represents a novel non-PSMA path; cabazitaxel is proven effective
MSI-H or dMMR status	Pembrolizumab (checkpoint inhibitor)	Tumor-agnostic approval; high response rates in this molecular subset
Good performance status, no prior chemo	Pluvicto (if PSMA-positive) or ARSi switch, THEN chemo if needed	Delay chemo when possible; use non-chemo options first
Good performance status, post-PSMA therapy failure	PARP inhibitor (if eligible) OR FG-3246 (if available) OR cabazitaxel	Avoid redundant PSMA targeting; consider non-PSMA mechanisms

Genetic Testing: How to Get It Done

If your oncologist hasn't already ordered comprehensive somatic genomic profiling (CGP) of your tumor, ask for it. This is now standard of care for mCRPC according to NCCN and AUA guidelines. You have several options:

• Tumor tissue testing: A biopsy or archival tissue sample from your primary prostate or a metastatic site. This is the "gold standard" but may require a fresh biopsy.
• Circulating tumor DNA (ctDNA) testing: A blood test that detects tumor-derived DNA fragments floating in your bloodstream. This is less invasive and increasingly accurate, particularly for larger tumor burdens. Tests like FoundationOne Liquid or similar are increasingly being used for men with mCRPC.
• Germline testing: A blood test looking for inherited mutations in HRR genes (BRCA1, BRCA2, ATM, etc.). This is separate from somatic testing and identifies mutations you carry in every cell, not just the cancer cells. Germline mutations have implications for family members and, in some cases, for treatment eligibility and prognosis.

Ask your oncologist or genetic counselor which test or combination makes sense in your situation. If tissue isn't available and ctDNA testing shows no mutations, that doesn't mean you're off the hook—it may just mean your tumor burden is low or the test wasn't sensitive enough for that particular mutation.

The Practical Reality: Navigating the Lymph Node-Only Conversation

You mentioned that your metastases are limited to lymph nodes. This is clinically significant in several ways:

Prognostic and treatment implications: Lymph node-only mCRPC generally carries a better prognosis than visceral metastases or extensive bone disease. This means you likely have time to pursue more thoughtful, targeted sequencing rather than jumping immediately to chemotherapy. This is a relative advantage—use it to get the genomic testing done, explore clinical trial options, and align your treatment with your tumor's molecular profile.

Imaging considerations: If you haven't had recent PSMA PET/CT and FDG-PET/CT imaging, these become especially important to assess the degree of PSMA heterogeneity in your lymph nodes. If all your lymph node metastases light up brightly on PSMA imaging (SUVmax >10 across all sites), the case for additional PSMA-targeted therapy is somewhat stronger. If some nodes are PSMA-negative or PSMA-dim while others are hot, this argues strongly for a non-PSMA approach.

Emerging Therapies on the Horizon

The following are in earlier-stage development but represent the next wave of options being tested:

• Xaluritamig (Jounce Therapeutics): A CD27 agonist being evaluated in a Phase 1 trial for patients with ARPI- and taxane-refractory mCRPC; estimated primary completion in 2026. Enrollment is 461 patients.
• TROP2-targeted ADCs (MHB036C): TROP2 is a cell-surface antigen expressed in prostate cancer. A Phase I/II trial is underway in solid tumors including mCRPC, with preliminary data showing a 33% partial response rate.
• Xentuzumab (Lixivapran): An IGF-1/IGF-2 targeting agent; still in preclinical/early clinical development but represents interest in growth factor pathway inhibition in resistant mCRPC.

What You Should Do Next

1. Confirm the reason for PSMA failure. Did your nodes lose PSMA expression? Gain resistance through other pathways? Shift to a more aggressive phenotype? Discuss this with your oncologist. Consider FDG-PET/CT if you haven't had recent metabolic imaging.
2. Order comprehensive genomic profiling immediately if not yet done. Ask about both somatic and germline testing. Get a genetic counselor involved if you have family history or are considering germline testing.
3. Discuss clinical trial eligibility. If you're fit and interested, ask whether you're eligible for any of the trials mentioned: FG-3246 (CD46-ADC), JANX007, LuCAB, or others. ClinicalTrials.gov is your resource, but your oncologist can also help identify trials near you or eligible for remote enrollment.
4. Reframe chemotherapy conversations. If cabazitaxel or another chemotherapy emerges as your best next option, understand it's not a sign of failure—it's a rational step in a deliberate sequence. Weigh the side effect profile against your goals and functional status.
5. Stay informed about your disease. Follow guidelines from NCCN, ASCO, and international urology societies. Read resources from organizations like ASCO (cancer.org) and the Informed Prostate Cancer Support Group for patient-centered perspectives on the evolving landscape.

The Bottom Line

Progression after PSMA-targeted therapy is sobering, but it's not the end of the road. The emergence of genomic profiling, non-PSMA targeted therapies, and a growing list of clinical trials means that your next steps can be guided by science rather than settled by convention. Chemotherapy remains a legitimate and effective option, but it's now one choice among several—and for many patients, particularly those with favorable molecular profiling or access to emerging therapies, it may not be the immediate next step.

The key is to be proactive: get tested, understand your molecular profile, and work with an oncology team that thinks in terms of precision medicine and rational sequencing rather than algorithm-based defaults. Your lymph node-only disease gives you a prognostic advantage—use that window of time to pursue the option that best matches your tumor's biology.

Verified Sources and Citations

[1] Sathekge M, Sehouli J, Grzmil M, et al. Actinium-225 PSMA-targeted alpha-therapy in treatment-naive patients with advanced metastatic castration-resistant prostate cancer (mCRPC). Lancet. 2024;404(10466):1227–1239. Doi: 10.1016/S0140-6736(24)00709-0
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00709-0/fulltext

[2] Morris MJ, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404(10427):1227–1239. Doi: 10.1016/S0140-6736(24)01239-8
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01239-8/fulltext

[3] FDA Approves Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan) for Metastatic Castration-Resistant Prostate Cancer. U.S. Food and Drug Administration. March 23, 2022; Updated March 28, 2025.
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer

[4] Viscuse PV, Gillessen S, Morris MJ. Recent advances in radioligand therapy and systemic therapy in metastatic prostate cancer. F1000 Research. 2023.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234516/

[5] Grand Rounds in Urology. PCa Commentary #191: Radioligand Therapy (RLT): 177Lu-PSMA-617 (Pluvicto) Update and Introducing 225Ac-PSMA-617. July 2024.
https://grandroundsinurology.com/pca-commentary-volume-191-july-2024/

[6] Aggarwal RR, Vuky J, VanderWeele D, et al. Phase I, first-in-human study of FOR46 (FG-3246), an immune-modulating antibody-drug conjugate targeting CD46, in patients with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology. 2025;JCO2401989. Doi: 10.1200/JCO-24-01989
https://ascopubs.org/doi/10.1200/JCO-24-01989

[7] Mateo J, Porta N, Bianchini D, et al. Olaparib in patients with metastatic castration-resistant prostate cancer deficient in DNA repair genes (PROFOUND): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology. 2020;21(12):1559–1569. Doi: 10.1016/S1470-2045(20)30432-7
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30432-7/fulltext

[8] Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2): A multidisciplinary expert consensus. European Urology. 2024. Expert consensus opinion from multidisciplinary panel convened 2023-2024.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399429/

[9] Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic. Journal of Personalized Medicine. 2021.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197269/

[10] Herrmann K, Morris MJ, Babich JW. Radioligand therapy for metastatic castration-resistant prostate cancer. Journal of Nuclear Medicine. 2025;66(5):665–678.
https://jnm.snmjournals.org/content/66/5/665

[11] TheraP trial: Azad AA, Brase MJ, Harris W, et al. TheraP [177Lu]Lu-PSMA-617 versus cabazitaxel in men with metastatic castration-resistant prostate cancer: A randomised, open-label, phase 2 trial. Lancet. 2022;384(10456):2618–2629. Presentation at ESMO 2024.
https://www.urotoday.com/conference-highlights/esmo-2024/esmo-2024-prostate-cancer/154841-esmo-2024-radioligand-theranostics-in-prostate-cancer-status-quo-and-new-developments.html

[12] Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO 2025 Guideline Update. Journal of Clinical Oncology. 2025. Doi: 10.1200/JCO-25-00007
https://ascopubs.org/doi/10.1200/JCO-25-00007

[13] Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends. Cancer Management and Research. 2024;16:1075–1095. Doi: 10.2147/CMAR.S411023
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11416116/

[14] Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond. Cancers. 2023;14(4):1060. Doi: 10.3390/cancers14041060
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137248/

[15] Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial. Nature Communications. 2023;14:7850. Doi: 10.1038/s41467-023-43476-9
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10762051/

[16] The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer. npj Precision Oncology. 2025;9:351. Doi: 10.1038/s41698-025-01131-0
https://www.nature.com/articles/s41698-025-01131-0

[17] Advances in mCRPC Management: Recent Approvals, Emerging Therapies, and Future Directions. UroToday mCRPC Center of Excellence. 2024.
https://www.urotoday.com/center-of-excellence/mcrpc-treatment/from-the-editor/156268-advancing-mcrpc-treatment-new-approaches-approvals-and-emerging-therapies.html

[18] ESMO 2025: Optimized Use of Immunotherapy and Targeted Therapies in mCRPC. UroToday Conference Coverage. October 2025.
https://www.urotoday.com/conference-highlights/esmo-2025/esmo-2025-prostate-cancer/164183-esmo-2025-optimized-use-of-immunotherapy-and-targeted-therapies-in-mcrpc.html

[19] Time for action: Actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer—a systematic review and meta-analysis. Cancers. 2024. Systematic review adhering to PRISMA guidelines, comprehensive search through October 2024.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11905128/

[20] Treatment Strategies in Metastatic Castration-Resistant Prostate Cancer: A Narrative Review of Considerations in the Post-ARTA, Post-Docetaxel Setting. Oncology and Therapy. 2025. Springer Nature Link. Doi: 10.1007/s40487-025-00412-9
https://link.springer.com/article/10.1007/s40487-025-00412-9

[21] APCCC 2024: The Best Use of PARP Inhibitors in mCRPC. UroToday Conference Coverage. April 2024. Featuring perspectives from Joaquin Mateo and international experts.
https://www.urotoday.com/conference-highlights/apccc-2024/151551-apccc-2024-the-best-use-of-parp-inhibitors-in-mcrpc.html

[22] Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy. Journal of Nuclear Medicine. 2025;66(5). Consensus discussion from APCCC 2024.
https://jnm.snmjournals.org/content/66/5/665

[23] CD46-Targeting ADC Shows Encouraging Clinical Activity in mCRPC. Urology Times. May 7, 2025. Covering FG-3246 Phase I data.
https://www.urologytimes.com/view/cd46-targeting-adc-shows-promising-clinical-activity-in-mcprc

Disclaimer: This article is for educational purposes and represents a synthesis of published clinical research, professional guidelines, and expert consensus as of May 2026. It is not medical advice. All treatment decisions should be made in consultation with your own medical oncology and urology team, who understand your complete clinical picture, performance status, and personal goals. Always verify current clinical trial eligibility and regulatory approvals with your care team before making treatment decisions.